Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

News
Article

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

Orbis and Heidelberg Engineering announce new partnership at ESCRS congress (Image credit: Adobe Stock/kerkezz)

(Image credit: Adobe Stock/kerkezz)

On Friday, Orbis, a global charity dedicated to fighting avoidable blindness, announced a partnership programme with Heidelberg Engineering. The announcement was made during the 41st ESCRS annual meeting. In a press release, Orbis announced the collaboration will make use of its e-learning and telemedicine platform Cybersight to train eyecare professionals.1

The global mission of Orbis seeks to serve the majority of people with vision loss and blindness; according to the non-profit, 90% of the 1.1 billion people affected live in low- or middle-income countries. Heidelberg Engineering will support live webinars via the Heidelberg Engineering Academy, with new sessions on optical coherence tomography (OCT) and related imaging technologies.

The company will also fund new research on retinoblastoma. This rare retinal cancer most commonly affects 9,000 paeditatric patients worldwide each year, most of whom are under 5 years of age. In a statement, Orbis said 92% percent of children diagnosed live in low- and middle-income countries. Barriers such as late diagnosis, limited accessibility to eye care, and lack of resources contribute to a 40% survival rate within 3 years of diagnosis.

Hunter Cherwek, MD, Vice President, Clinical Services & Technologies at Orbis International, said, “Orbis is delighted to be partnering with Heidelberg Engineering. Retinoblastoma outcomes for children in low-and-middle income countries could be significantly improved with earlier diagnosis and enhanced treatment.”

“As a global leader in imaging and health care technology, Heidelberg Engineering’s generous contribution and partnership will mean we can both offer enhanced knowledge for eye care practitioners via Cybersight, and pioneer new research that will help improve outcomes for children facing retinoblastoma across the world,” Cherwek added.

Reference
1. Leading eye care charity Orbis announces a new partnership with Heidelberg Engineering. News release. Orbis UK. Published 8 September, 2023.
Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.